UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| (Address of Principal Executive Offices) | ( Zip Code) |
Registrant’s telephone number, including
area code: (
Not applicable
(Former Name or Former Address,
if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07. Submission of Matters to a Vote of Security Holders.
Due to technical difficulties with the third-party hosting site, Carisma Therapeutics Inc. (the “Company”) commenced and adjourned its virtual annual meeting of stockholders scheduled for June 13, 2024, without any business being conducted. At the Company’s reconvened virtual annual meeting of stockholders held on June 14, 2024, the Company’s stockholders voted on the following proposals:
1. The following nominees were elected to the Company’s Board of Directors as Class I directors for terms expiring at the 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified.
| Votes For | Votes Withheld | Broker Non-Votes | ||||||||||
| John Hohneker, M.D. | 16,741,881 | 612,693 | 7,462,405 | |||||||||
| Michael Torok | 16,023,508 | 1,331,066 | 7,462,405 | |||||||||
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.
| Votes For: | 16,719,502 | |||
| Votes Against: | 575,356 | |||
| Votes Abstaining: | 59,716 | |||
| Broker Non-Votes: | 7,462,405 |
3. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified.
| Votes For: | 24,389,393 | |||
| Votes Against: | 172,754 | |||
| Votes Abstaining: | 254,832 | |||
| Broker Non-Votes: | — |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CARISMA THERAPEUTICS INC. | ||
| By : |
/s/ Steven Kelly | |
| Date: June 14, 2024 | Steven Kelly | |
| President and Chief Executive Officer | ||